• LAST PRICE
    0.0397
  • TODAY'S CHANGE (%)
    Trending Up0.0197 (98.5000%)
  • Bid / Lots
    ---/ ---
  • Ask / Lots
    ---/ ---
  • Open / Previous Close
    0.0200 / 0.0200
  • Day Range
    Low 0.0131
    High 0.0397
  • 52 Week Range
    Low 0.0014
    High 2.1000
  • Volume
    27,054
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Monday's close: 0.02
TimeVolumePHASQ
09:32 ET99770.02
09:35 ET20000.0131
10:42 ET33300.0397
11:12 ET3000.0132
11:21 ET10000.0133
12:12 ET20000.02115
12:35 ET10000.0136
03:19 ET74150.0397
Data delayed at least 15 minutes.
No documents available
0 New Today
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesPHASQ
PhaseBio Pharmaceuticals Inc
997.2K
0.0x
---
United StatesROSGQ
Rosetta Genomics Ltd
590.0
0.0x
---
United StatesPTE
PolarityTE Inc
5.7M
-0.2x
---
United StatesMCUJF
Medicure Inc
9.6M
4.7x
---
United StatesNBY
NovaBay Pharmaceuticals Inc
4.4M
-0.4x
---
United StatesISCO
International Stem Cell Corp
1.6M
-2.5x
---
As of 2023-02-01

Company Information

PhaseBio Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company that is focused on the development and commercialization of therapies for cardiopulmonary diseases. The Company’s product pipeline includes Bentracimab (PB2452), PB6440 (for treatment-resistant Hypertension), pemziviptadil (PB1046), GLP2-ELP and CNP-ELP. The Company conducting REVERSE-IT, its pivotal Phase III clinical trial of bentracimab. PB2452 is a novel recombinant human monoclonal antibody antigen-binding fragment, designed to reverse the antiplatelet activity of ticagrelor in the event of major bleeding. PB6440 is an oral selective aldosterone synthase inhibitor for treatment of resistant hypertension. Pemziviptadil (PB1046), is a novel, subcutaneously-injected VIP analogue, which is a recombinant fusion protein composed of VIP and its proprietary ELP technology. ELP technology platform is a growth engine for additional medicines for cardiovascular diseases.

Contact Information

Headquarters
1 Great Valley Pkwy Ste 30MALVERN, PA, United States 19355-1423
Phone
610-981-6500
Fax
302-531-3150

Executives

Independent Chairman of the Board, Co-Founder
Clay Thorp
Chief Executive Officer, Director
Jonathan Mow
Principal Financial Officer
Lawrence Perkins
Senior Vice President, General Counsel, Company Secretary
Kristophe Hanson
Senior Vice President of Human Resources
Glen Burkhardt

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$997.2K
Revenue (TTM)
$818.0K
Shares Outstanding
49.9M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
2.31
EPS
$-2.13
Book Value
$-1.93
P/E Ratio
0.0x
Price/Sales (TTM)
1.2
Price/Cash Flow (TTM)
---
Operating Margin
-12,738.63%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.